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Tryptophanyl-tRNA synthetases (TrpRSs) catalyze the aminoacylation of tRNATrp. Previously, I dem-
onstrated that Zn2+-depleted human TrpRS is enzymatically inactive and that binding of Zn2+ or
heme to human TrpRS stimulates its aminoacylation activity. In the present study, bovine and
mouse TrpRSs were found to be constitutively active regardless of the presence of Zn2+ or ferripro-
toporphyrin IX chloride. Mutagenesis experiments demonstrated that the human H130R mutant is
constitutively active and that the bovine R135H, E438A double mutant binds with Zn2+ or heme to
enhance its aminoacylation activity as does human wild-type TrpRS. These results provide the ﬁrst
evidence of species-speciﬁc regulation of TrpRS activity.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction man full-length TrpRS at a stoichiometric ratio of 1:1 heme:proteinAminoacyl-tRNA synthetases are key enzymes in the process of
protein biosynthesis and catalyze the aminoacylation of their cog-
nate tRNAs [1]. Human tryptophanyl-tRNA synthetase (TrpRS)
plays a role in protein synthesis and in angiogenic signal transduc-
tion pathways [2]. TrpRS is the only aminoacyl-tRNA synthetase
whose expression is induced by interferon (IFN)-c [3–5]. Previ-
ously, I demonstrated that human TrpRS is a Zn2+- or heme-binding
protein and that the Zn2+ or heme is indispensable for aminoacyla-
tion by this protein [6]. The bond between Zn2+ and TrpRS is rather
labile: indeed, even dialysis in the absence of a chelating agent
leads to a signiﬁcant decrease in Zn2+ content [7]. Heme is an iron
protoporphyrin IX complex that serves as a prosthetic group for
many proteins [8]. A heme biosynthesis inhibitor, succinylacetone
(SA), was found to inhibit cellular TrpRS activity in IFN-c-activated
cells without affecting TrpRS protein expression [6]. In addition,
supplementation of lysates from SA-treated cells with heme re-
stored TrpRS activity to control levels [6]. Biochemical analyses
demonstrated that heme interacts strongly with Zn2+-depleted hu-chemical Societies. Published by E
ase; Trp, tryptophan; hemin,
hool of Arts and Sciences, The
153-8902, Japan. Fax: +81 3to enhance the aminoacylation activity signiﬁcantly [6].
In the present study, I investigated whether the aminoacylation
activity of bovine or mouse TrpRS depends on the presence of Zn2+
or ferriprotoporphyrin IX chloride (hemin). Further insight into the
Zn2+- or heme-binding properties of TrpRS was gained by using
site-directed mutagenesis.
2. Materials and methods
2.1. Chemicals
Brewer’s yeast tRNA was purchased from Roche Diagnostics.
Hemin (Sigma) was used as supplied without further puriﬁcation.
2.2. Aminoacylation assays
Aminoacylation activity was assayed at ambient temperature
(20 C) in buffer containing the following: 150 mM Tris–HCl
(pH 7.5), 150 mM KCl, 10 mM MgCl2, 4 mM ATP, and 34 lM tryp-
tophan (Trp) [1 lM [3H]Trp (Amersham Biosciences)], as described
in [6].
2.3. Preparation of proteins
cDNA fragments of human full-length TrpRS (a.a. 1–471), bo-
vine full-length TrpRS (a.a. 1–476), and mouse full-length TrpRSlsevier B.V. All rights reserved.
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Fig. 1. Aminoacylation activity of TrpRSs toward yeast tRNATrp in the absence or
presence of Zn2+ (1 lM) or hemin (1 lM). Aminoacylation efﬁciencies were
calculated as pmol/min of aminoacylated tRNATrp, which was synthesized during
a 1 min incubation. The assays included 200 nM TrpRS and 500 lM yeast tRNA.
Values represent the means ± standard deviation from three experiments. (A)
Aminoacylation activity of human, bovine and mouse wild-type TrpRSs. (B)
Aminoacylation activity of human H130R TrpRS, bovine single (R135H), single
(E438A), and double (R135H, E438A) TrpRS mutants.
Table 1
Absorption maxima of the Soret band of heme in the presence of Zn2+-depleted TrpRS
at a protein:heme ratio of 1:0.7.
Sample Soret peak (nm)
Human wild-type TrpRS 413
Bovine wild-type TrpRS 391
Mouse wild-type TrpRS 389
Human H130R TrpRS single mutant 393
Bovine R135H TrpRS single mutant 388
Bovine R135H,E438A TrpRS double mutant 413
Bovine E438A TrpRS single mutant 389
Free heme 391
230 K. Wakasugi / FEBS Letters 584 (2010) 229–232(a.a. 1–475) were separately cloned into the pET20b (Novagen)
expression vector to give a gene product with a C-terminal tag of
six histidine residues (6His-tag). A QuikChange™ site-directed
mutagenesis system (Stratagene) was used to introduce substitu-
tions at speciﬁc sites. The constructs were conﬁrmed by DNA
sequencing (FASMAC Co. Ltd., DNA sequencing services). The
expression constructs were introduced into Escherichia coli
BL21(DE3) (Novagen), and the recombinant 6His-tagged proteins
were puriﬁed on a nickel afﬁnity column (HisBind resin; Nova-
gen) from the supernatant of lysed cells, as described in [6]. After
puriﬁcation, recombinant TrpRS proteins were dialyzed against
50 mM Tris–HCl (pH 7.5) containing 10 mM EDTA for 1 day. EDTA
was subsequently removed from the solution by further dialysis.
2.4. Atomic absorption spectrophotometry
The amounts of Zn, Fe, Ni, Cu, Mn, or Co bound to TrpRS proteins
were determined by atomic absorption spectrophotometry using a
polarized Zeeman atomic absorption spectrometer, type Z-8100
(Hitachi).
2.5. Visible spectra
Electronic absorption spectra of puriﬁed proteins were recorded
with a UV/visible spectrophotometer (UV-2450; Shimadzu) at
ambient temperature (20 C). Spectra were recorded in 20 mM
sodium phosphate buffer (pH 7.4) containing 0.1 M NaCl.
3. Results
3.1. Bovine and mouse TrpRSs are constitutively active regardless of
the presence of Zn2+ or hemin
Bovine and mouse TrpRSs were puriﬁed following expression in
E. coli. The recombinant TrpRSs were dialyzed for one day to gen-
erate the Zn2+-depleted forms. Atomic absorption analysis was per-
formed on the dialyzed TrpRSs to determine Zn, Fe, Ni, Cu, Mn, and
Co content. This analysis revealed that the molar ratio of Zn to pro-
tein was less than 10% (Supplementary Fig. S1). As shown in Sup-
plementary Fig. S1, each TrpRS bound to Zn preferentially as
compared to Fe or Ni. Moreover, the molar ratio of Mn, Cu, or Co
bound to the protein was estimated to be less than 0.1% (data
not shown).
Since previous data showed that eukaryotic TrpRSs can amino-
acylate yeast tRNATrp [6,9,10], I ﬁrst investigated the aminoacyla-
tion activity of the recombinant TrpRSs toward yeast tRNATrp in
the absence or presence of Zn2+ or hemin. As shown in Fig. 1A, bo-
vine and mouse TrpRSs were enzymatically active regardless of the
presence of Zn2+ or hemin in the reaction mixture. In contrast, the
aminoacylation activity of Zn2+-depleted human TrpRS was signif-
icantly lower than either Zn2+-depleted bovine or mouse TrpRS
(Fig. 1A). The presence of Zn2+ or hemin in the reaction mixture
stimulated the aminoacylation activity of human TrpRS to a level
comparable to that of the mouse or bovine TrpRS (Fig. 1A).
The visible absorption spectrum of Zn2+-depleted human TrpRS
showed a strong Soret band at 413 nm following addition of hemin
to the buffer solution (Table 1) [6]. In contrast, no such red shift in
the Soret band of heme was observed in the presence of bovine or
mouse TrpRS (Table 1), indicating that these proteins cannot bind
heme.
3.2. Human H130R TrpRS mutant is constitutively active like bovine
and mouse wild-type TrpRSs
Sequence alignment of the human, bovine and mouse TrpRSs
(Fig. 2A) shows that bovine and mouse TrpRSs have an arginine(Arg) residue at the position corresponding to His130 of human
TrpRS. To investigate the role of this Arg residue, I prepared the hu-
man H130R mutant [6]. Previously I showed that the H130R muta-
tion compromised the ability of human TrpRS to bind heme [6]. X-
ray structural analyses of human TrpRS suggested that Arg130
might interact with Glu408 in the H130R mutant (Fig. 2B). Since
residues 130 and 408 are located in the Rossmann fold domain
and the anticodon-binding domain, respectively, an interaction be-
tween Arg130 and Glu408 may block crucial interdomain confor-
mational changes necessary for binding to heme. I next
A
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Fig. 2. Structure of TrpRSs. (A) Sequence alignment of human, bovine and mouse
TrpRSs. The multiple sequence alignment was performed by Clustal W followed by
manual adjustments. The numbers above the sequences represent the amino acid
positions of the human TrpRS. The numbers in parentheses represent the amino
acid positions of the bovine TrpRS. (B) Crucial residues for heme- or Zn2+-binding in
TrpRS. The crystal structure of the human full-length TrpRS with bound trypto-
phanyl-adenylate (purple) (Protein Data Bank ID code 1R6T) shows that TrpRS
consists of an N-terminal appended domain (gray), a Rossmann fold catalytic
domain (82–353; gray), and an anticodon-binding domain (354–467; yellow).
His129 and His130 are indicated by pink sticks. Arg127, Arg133, and Arg134 are
indicated in red. Glu408 and Asp410 are indicated in blue. Lys412 and Ala433 are
indicated in red and green, respectively.
0
0.04
0.08
0.12
0.16
0.2
0.24
0.28
300 400 500 600 700
A
bs
or
ba
nc
e
wavelength (nm)
413 nm
0
0.01
0.02
0.03
0.04
0.05
0.06
0 0.5 1 1.5 2 2.5
ΔA
bs
or
ba
nc
e
[hemin]/[protein]
0.08
0.12
0.16
0.2
0.24
0.28
A
bs
or
ba
nc
e
391 nm
0.1
0.15
0.2
0.25
0.3
A
bs
or
ba
nc
e
392 nm
A B
DC
K. Wakasugi / FEBS Letters 584 (2010) 229–232 231investigated the aminoacylation activity of human H130R TrpRS in
the absence or presence of Zn2+ or hemin. As observed for the bo-
vine and mouse wild-type TrpRSs, human H130R TrpRS was highly
active regardless of the presence of Zn2+ or hemin in the reaction
mixture (Fig. 1A and B).0
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Fig. 3. Spectroscopic analyses of bovine R135H, E438A TrpRS double mutant. (A)
Electronic absorption spectrum of the ferric form of heme bound to Zn2+-depleted
bovine double mutant (R135H, E438A) TrpRS. Spectra were recorded in 20 mM
sodium phosphate buffer (pH 7.4) containing 0.1 M NaCl. (B) Spectroscopic titration
of Zn2+-depleted bovine R135H, E438A double mutant with hemin. Titration
experiments were performed in cuvettes by adding aliquots of hemin stock solution
to the sample cuvette. An identical aliquot of hemin was added to the reference
cuvette containing only buffer. The changes in absorption spectra at 413 nm were
measured. (C) Competition of Zn2+ with heme for binding to bovine double mutant
(R135H, E438A) TrpRS. TrpRS–heme complex was formed by incubating TrpRS
(5.4 lM) with hemin (5.5 lM) for 10 min in 20 mM sodium phosphate buffer (pH
7.4) containing 0.1 M NaCl (dashed line), followed by incubation for 30 min with
10 lM Zn2+ (solid line). (D) Addition of hemin does not displace Zn2+ from Zn2+-
bound bovine double mutant (R135H, E438A) TrpRS. TrpRS (5.4 lM) was incubated
with 10 lM Zn2+ for 30 min followed by addition of 5.5 lM hemin for 10 min.3.3. Bovine R135H, E438A TrpRS double mutant binds Zn2+ or heme to
enhance its aminoacylation activity
Next, to gain further insight into differences in the mechanism
of the regulation of the aminoacylation activity of mammalian
TrpRSs, I endeavored to impart the Zn2+- and heme-dependence
of the human TrpRS upon the bovine TrpRS by genetic engineering.
Sequence alignment of the human and bovine TrpRSs indicated
that the His130 residue of human TrpRS corresponds to Arg135
of the bovine TrpRS (Fig. 2A). I engineered the bovine R135H TrpRS
mutant and investigated the characteristics of its aminoacylation
activity. As shown in Fig. 1B, bovine R135H TrpRS was constitu-
tively active even following depletion of Zn2+. Since X-ray struc-
tural analysis of the human TrpRS suggested that Glu438 of the
bovine TrpRS (corresponding to Ala433 in human TrpRS) mightinteract with Lys417 (corresponding to Lys412 in human TrpRS)
(Fig. 2B), I next engineered the bovine R135H, E438A double mu-
tant. This mutant was inactive following depletion of Zn2+, and
its aminoacylation activity was enhanced in the presence of Zn2+
or hemin, as was observed for the human wild-type TrpRS
(Fig. 1B). In contrast, Zn2+ or heme did not inﬂuence the aminoacy-
lation activity of the bovine E438A TrpRS single mutant (Fig. 1B).
Atomic absorption spectrophotometry revealed that the molar ra-
tio of Zn per each human or bovine TrpRS mutant protein was less
than 10% (Supplementary Fig. S2).
The addition of hemin to the Zn2+-depleted bovine R135H,
E438A double mutant gave rise to a visible absorption spectrum
showing a strong Soret band at 413 nm (Table 1 and Fig. 3A). The
Soret band corresponding to free heme under the same conditions
is observed at 391 nm (Table 1). The appearance of a Soret band at
413 nm indicates the formation of a complex between TrpRS and
heme. The spectral pattern of the TrpRS–heme complexes shown
in Fig. 3A is typical of the ferric low-spin state of the heme
[11,12]. The complex formed between heme and TrpRS was quan-
tiﬁed from the spectral changes at 413 nm that were observed in
the visible absorption spectra of the mixture. As shown in
Fig. 3B, the curve resulting from titration of hemin with TrpRS
showed that heme binds to TrpRS in a saturable manner and in a
stoichiometric ratio of 1:1 heme:protein.
Next, competitive binding studies were performed to determine
whether Zn2+ affects the binding of heme to TrpRS. When Zn2+ was
added to preformed heme–TrpRS complex, the Soret band was
232 K. Wakasugi / FEBS Letters 584 (2010) 229–232shifted from 413 nm to 391 nm (Fig. 3C), suggesting that addition
of Zn2+ to the heme–TrpRS complex displaced the heme. No signif-
icant spectral changes in the Soret region were observed upon
addition of hemin to the Zn2+-bound bovine R135H, E438A TrpRS
double mutant (Fig. 3D), suggesting that heme does not bind to
the Zn2+-bound form of the enzyme. This result may reﬂect a con-
formational change within or around the heme-binding site fol-
lowing interaction with Zn2+.
4. Discussion
Previously, human TrpRS was found to exist in two forms: an
enzymatically active Zn2+- or heme-bound form and an inactive
Zn2+-depleted form [6]. In the present study, I have shown that bo-
vine and mouse TrpRSs are constitutively active regardless of the
presence of Zn2+ or hemin. What is the physiological role for an
enzymatically inactive form speciﬁc to the human TrpRS?
The expression of human TrpRS is strongly increased in re-
sponse to IFN-c [3–5]. Homo sapiens is the only species in which
TrpRS expression has been reported to be induced by IFN-c treat-
ment. My previous studies demonstrated that the aminoacylation
activity of human TrpRS increased 1.5-fold upon addition of
hemin to IFN-c-activated cells, indicating that a signiﬁcant portion
of the TrpRS expressed in these cells is present as the apoprotein,
which does not contain Zn2+ [6]. In other words, when expression
of human TrpRS is increased in response to IFN-c, some of the new-
ly produced TrpRS protein is in the Zn2+-free form, such that the
aminoacylation activity of this new protein is therefore sensitive
to the level of heme [6].
It has been also noted that IFN-c induces accumulation of diad-
enosine triphosphate (Ap3A) in cultured human cells [13]. Diade-
nosine oligophosphates (ApnA) have been proposed to act as
intracellular and extracellular signaling molecules in animal cells
[14]. The ratio of Ap3A to Ap4A (Ap3A/Ap4A) is sensitive to the cel-
lular status: a high Ap4A/Ap3A ratio is associated with cell death
and a high Ap3A/Ap4A ratio is associated with cell differentiation
[15,16]. It has been reported that Ap3A synthesis is inhibited by
competitive inhibitors of TrpRS that prevent tryptophanyl-adenyl-
ate formation, implying that Ap3A accumulation results from hu-
man TrpRS activity. Therefore, the physiological function of the
inactive Zn2+-depleted form of human TrpRS may be related to no-
vel non-canonical functions, such as Ap3A synthesis in IFN-c-acti-
vated cells.
Previously, it was reported that bovine TrpRS requires Zn2+-
binding for its aminoacylation activity [7]. However, the present
study has shown that Zn2+-depleted bovine TrpRS remains enzy-
matically active. This discrepancy may be due to differences in pro-
tein modiﬁcation, because bovine TrpRS puriﬁed from the pancreas
is phosphorylated and glycosylated [17,18]. Further studies are
necessary to investigate whether bovine TrpRS can take on an inac-
tive conformation after protein modiﬁcation.
Taken together, the present data reveals species-speciﬁc differ-
ences in regulation of the aminoacylation activity of mammalian
TrpRSs and indicates that the amino acid residue corresponding
to His130 in the human TrpRS is crucial for such regulation. Further
studies to investigate the physiological roles of the inactive form
speciﬁc to the human TrpRS are underway.Acknowledgments
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